D
uring the last few years, there has been an exponential rise in understanding functions and signal transduction mechanisms for angiotensin II (Ang II) type 2 receptors (AT 2 s). 1, 2 These studies are particularly relevant in view of the pivotal role of upregulation of AT 2 in mediating tissue remodeling in many cardiovascular diseases, including vascular injury, atherosclerosis, cardiac hypertrophy, myocardial infarction, and congestive heart failure. 1 Furthermore, Ang II type 1 receptor (AT 1 ) antagonists, commonly used for treatment of hypertension and congestive heart failure, increase plasma levels of Ang II and upregulate AT 2 expression. Under these conditions, the increase in AT 2 is unopposed by AT 1 . 1, 3 Thus, understanding the role of AT 2 in cardiovascular remodeling as well as the consequences of AT 2 stimulation or inhibition during medical therapy is clinically important. AT 2 s only partially share the signaling mechanisms with AT 1 s and, in fact, counteract the signaling mechanisms activated by AT 1 s 2 ( Figure) . This negative nature of AT 2 signaling has made the elucidation of its function more difficult than that of AT 1 . However, recent studies on the cardiovascular functions of AT 2 seem to have reached a consensus: AT 2 s exert growth inhibitory effects either by suppressing cell proliferation and hypertrophy 4, 5 or by stimulating apoptosis. 1, 2, 6 These actions alone may not explain the diverse cardiovascular phenomena attributed to AT 2 , resulting in unanswered questions. Why are AT 2 s abundant in growing fetal tissues? Why are AT 2 s abundant in tissues undergoing remodeling? Recently, an elegant genetic study has provided an answer to some of these questions, showing that an important function of AT 2 in the fetal kidney is to stimulate apoptosis. Targeted deletion of AT 2 causes malformation of the kidney and urinary tract similar to that observed in human CAKUT (congenital anomalies of the kidney and urinary tract), a malformation caused by delayed apoptosis of undifferentiated mesenchymal cells. 7 Although execution of apoptosis is certainly an important function of AT 2 during postnatal (pathological) cardiovascular remodeling, some studies have pointed out that AT 2 s may also be involved in inflammatory and cell growth processes. 8 -11 In this issue of Circulation Research, Ruiz-Ortega et al 12 show that Ang II activates nuclear factor-B (NF-B) through both AT 1 and AT 2 in vascular smooth muscle cells. NF-B is a ubiquitous transcription factor of particular importance in inflammatory responses. 13 Many stimuli relevant to cardiovascular diseases, including proinflammatory cytokines (interleukin [IL]-1␤ and tumor necrosis factor-␣ [TNF-␣]), signals elicited by ischemic stress (nitric oxide [NO] and reactive oxygen species), and mechanical forces, have been shown to activate NF-B. Activation of NF-B leads to coordinated increases in the expression of many genes whose products mediate inflammatory responses, including cytokines, chemokines, and adhesion molecules. 13 Although activation of NF-B by AT 1 has been demonstrated previously, 14 the study by Ruiz-Ortega et al 12 is the first to show the linkage between AT 2 and NF-B and thus potentially clarifies the mechanism of many presently unexplained cardiovascular phenomena known to be mediated by AT 2 .
Functional Roles of the AT 2 /NF-B Pathway
As Ruiz-Ortega et al 12 15 and cyclooxygenase-2, 16 which mediate NO and prostaglandin and thromboxane production, respectively, in inflammatory diseases. NO synthesis and subsequent production of cGMP are stimulated by AT 2 in many organs. 17 Induction of cyclooxygenase-2 and activation of NF-B have been observed in fibrotic scars in the myocardium of failing human hearts. 18 Remarkably, AT 2 s in human hearts are predominantly localized in fibroblasts present in the interstitial region, 1 suggesting that AT 2 may be responsible for progression of inflammation and interstitial fibrosis during cardiac remodeling. Stimulation of AT 2 generally inhibits growth of vascular smooth muscle cells 4 and cardiac myocytes, 5 but, paradoxically, it may also be involved in cell growth. For example, AT 2 blockade inhibits medial smooth muscle hypertrophy and fibrosis in the thoracic aorta of Ang II-infused rats 9 and spontaneously hypertensive rats. 10 Because these growth stimulatory effects are seen only in vivo (and have not been reported in pure smooth muscle cell cultures), upregulation of cytokines and cell adhesion molecules by the AT 2 /NF-B pathway, attraction of inflammatory cells, and additional amplification of trophic (paracrine) factors in vivo may be responsible for these AT 2 -mediated cell growth responses. Recently, a preliminary study suggested that pressure overload-induced cardiac hypertrophy is completely suppressed in mice with targeted
The opinions expressed in this editorial are not necessarily those of the editors or of the American Heart Association.deletion of AT 2 . 11 Although this observation seems contradictory to known acute antihypertrophic effects of AT 2 , 5 the AT 2 /NF-B pathway may chronically regulate expression of cytokines, thereby preparing the trophic environment for hypertrophy and remodeling. Alternatively, stretch-induced secretion of Ang II and subsequent amplification of inflammatory cytokines through the AT 2 /NF-B pathway may mediate pressure overload-induced cardiac hypertrophy. In fact, macrophage infiltration has been demonstrated in the myocardium subjected to mechanical overload. 19 Expression of AT 2 is upregulated by IL-1␤, insulin, and insulin-like growth factor and downregulated by glucocorticoids. 20 All these stimuli exert directionally similar effects on NF-B and AT 2 . This raises the possibility that the NF-B site found in the AT 2 promoter may mediate transcription of AT 2 . Products of genes that are regulated by NF-B in many cases cause activation of NF-B, and this positive-feedback loop can amplify and perpetuate local inflammatory responses. 13 This suggests that the AT 2 /NF-B pathway could be a component of such an amplification loop, which eventually enhances expression of both cytokines and AT 2 . Increased production of angiotensinogen by NF-B may additionally enhance the amplification loop. 21 As noted above, stimulation of AT 2 promotes apoptosis, whereas activation of NF-B generally promotes cell survival. Although this seems contradictory, NF-B can promote apoptosis by increasing expression of Fas and Fas ligand in fibroblasts 22 or decreasing bcl-2 expression in aortic endothelial cells. 23 This cell-type specific action of NF-B may in part explain why AT 2 does not promote apoptosis in some cell types. 24 
Signaling Mechanism of NF-B Activation by Ang II
Another interesting aspect of the work by Ruiz-Ortega et al 12 is that both AT 1 and AT 2 are able to activate NF-B. AT 2 activates protein phosphatases, including SHP-1, PP2A, and MKP-1, thereby inactivating tyrosine kinases and mitogen-activated protein kinases stimulated by AT 1 . 2 It is interesting that NF-B activation is one of the few examples reported thus far in which AT 1 and AT 2 share the signaling mechanism at least in part ( Figure) . Although both AT 1 and AT 2 stimulation cause degradation of inhibitor B (IB), 12 an essential step for nuclear translocation of NF-B, the mechanism leading to IB degradation by AT 1 and AT 2 stimulation remains to be clarified. Degradation of IB depends on phosphorylation of the two N-terminus serines by IB kinase, and the phosphorylated IB undergoes polyubiquitination and proteasome degradation. 25 Degradation of IB can be also mediated by phosphorylation of IB at tyrosine 42 or by unknown mechanisms involving protein tyrosine phosphatases. 25, 26 Therefore, it will be interesting to determine whether NF-B activation by AT 1 and AT 2 is mediated by either IB kinase-dependent mechanisms or other mechanisms in which tyrosine kinases or phosphatases (directly or indirectly) modulate IB degradation. Ruiz-Ortega et al 12 suggest that oxygen radicals and ceramide are common mediators of NF-B activation by AT 1 and AT 2 . However, how AT 2 stimulates production of oxygen radicals and ceramide in cardiovascular cell types remains to be elucidated.
Unresolved Questions
Several important questions remain unanswered. First, in cultured smooth muscle cells, Ang II-induced increases in MCP-1 and angiotensinogen, well-known targets of NF-B, were mediated predominantly by AT 1 , despite both AT 1 and AT 2 stimulation activating NF-B in this cell type. 12 Because AT 1 is the predominant Ang II receptor subtype in cultured aortic vascular smooth muscle cells, the possibility remains that these NF-B targets may be regulated more potently by AT 2 when expression of AT 2 is upregulated in pathological conditions. It is also possible that AT 1 and AT 2 regulate different molecules through NF-B. For example, the AT 1 / NF-B pathway may regulate predominantly proinflammatory cytokines, whereas the AT 2 /NF-B pathway may have different targets. The mechanisms by which AT 1 and AT 2 regulate distinct NF-B targets remain to be clarified. Because NF-B is known to function in concert with other transcription factors 13 such as AP-1 and C/EBP, these cofactors may be regulated differentially by AT 1 and AT 2 . Another important question is whether the AT 2 /NF-B pathway always exerts a beneficial action in cardiovascular diseases. 1 The answer is not simple, considering that NF-B activation can be both beneficial and detrimental. For example, NF-B activation is essential for the development of the cardioprotective effects of preconditioning. 27 On the other hand, many studies have shown that inhibition of NF-B can also have a salutary effect on cardiovascular diseases. For example, in vivo transfer of NF-B decoy oligonucleotides reduces the extent of myocardial infarction and reperfusion injury. 28, 29 Inhibition of NF-B reduces Ang II-induced organ damage in the heart and kidney by preventing inflammatory mediators. 30 In the vasculature, inhibition of NF-B suppresses development of atherosclerotic lesions by preventing inflammation, 31 smooth muscle cell proliferation, 32 and dysregulation of apoptosis. 33 In a recent review, Matsubara 1 discussed the potential advantages of shunting Ang II toward AT 2 (during AT 1 blockade) in the treatment of cardiovascular diseases. This hypothesis is well supported by the results of a recent study showing that losartan was associated with a lower mortality rate than captopril in the treatment of older heart failure patients. 34 It has been shown that cardioprotective effects of AT 1 antagonists in a rat model of heart failure are prevented by AT 2 blockade. 35 It will be extremely important to identify the targets of the AT 2 /NF-B pathway in each disease condition and evaluate in which disease states stimulation of AT 2 could be beneficial.
